RecruitingDiabetes Mellitus, Type 1OverweightObesity
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Eligible age
18–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
- ✓ Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
- ✓ Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening
You may not qualify if…
- ✕ Participants who have a known clinically significant gastric emptying abnormality
- ✕ Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
- ✕ Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists
Where it's recruiting
Florida
Miami
Source: ClinicalTrials.gov · NCT07803744 · last updated 2026-09-23